Introduction

Metastasis is a complex process in which a tumor cell leaves the original site of disease, called the primary tumor, to spread to others parts of the body. Cancer cells can break away from a primary tumor, enter the blood vessels, circulate through the bloodstream, and be deposited in other organs of the body far from the primary tumor. When tumor cells metastasize to distant organs, the new tumor is called secondary or metastatic tumor.¹

Epidemiology

Most tumors can metastasize. The most common sites of metastasis from solid tumors are the lungs, liver, and bones. However, the frequency, location, and patterns of metastases will depend on the primary tumor. Certain tumors rarely metastasize whereas some cancers tend to metastasize earlier than others.² The presence of metastatic disease may also be correlated with the tumoral histology. Undifferentiated, anaplastic, and high-grade tumors have a tendency to give more metastases than well-differentiated and low-grade tumors.³ The cells in a metastatic tumor resemble those in the primary tumor. However, when the metastatic tumor is undifferentiated, the pathologist can use several adjuvant techniques, such as immunohistochemistry, to try to identify the origin of the primary tumor. In rare cases, patients will have metastatic disease without a primary tumor found, and these patients are considered to have a cancer of an unknown primary tumor.⁴

Clinical Presentation

Metastatic disease is usually present in late stages of the cancer. However, when metastases are present early in the course of the disease, the type and frequency of the symptoms will depend on the location and size of the metastatic lesions. For example, symptoms of liver impairment such as development of jaundice and hepatomegaly can indicate that the cancer has spread to the liver. Neurologic symptoms such as headaches and seizures may indicate the presence of brain metastases. Bone metastases usually present as bone pain.

Diagnosis

The diagnosis of the presence of metastatic disease is one of the most important steps in the staging of patients with cancer. The detection of metastatic disease has an important role in the prognosis and treatment of cancer patients. Several imaging modalities may be used in the assessment of presence of metastatic disease. Among them, ultrasonography (US) has been widely used to detect intra-abdominal and pelvic metastases owing to its advantages such as widespread availability, noninvasiveness, and relative low cost. The introduction of multidetector row computed tomography (MDCT) technology has allowed computed tomography (CT) to be one of the most common imaging methods used in the evaluation of presence of metastatic disease. Moreover, magnetic resonance imaging (MRI), a nonionizing imaging technique with intrinsic multiplanar capabilities, has elevated sensitivity in the detection of metastatic disease owing to its high contrast resolution.

Treatment

Treatment for metastatic disease usually depends on several factors including the size and location of the metastasis, the patient’s age and general health, and the types of treatments the patient has had in the past. Patients with a single metastasis or single site of metastatic disease need to be evaluated for possible curative treatment usually with surgical resection. However, when there are multiple metastases, systemic treatment is necessary. Systemic therapy options include chemotherapy, radiation therapy, biologic therapy, clinical trials, or a combination of these.

Patterns of Tumor Spread

The three principal pathways of tumor dissemination are hematogenic, lymphatic, and local invasion. The purpose of this chapter is to review hematogenous metastasis to intra-abdominal and pelvic organs. We divide our chapter by individual organ.

Key Points What the surgeon, radiation oncologist, and medical oncologist want to know

• The surgeon wants to know the presence of metastases, the number and size of the lesions, multifocality, and vascular involvement to plan resection.

• The radiation oncologist needs to know the location, size, and relationship of tumor to radiosensitive organs to plan radiation therapy field.

• The medical oncologist wants to know the number, location, and size of the lesions in the baseline study and the response to chemotherapy on follow-up imaging.

Liver

The most common solid organ to receive metastatic disease is the liver. Approximately 50% to 60% of patients who die of cancer have hepatic metastases at autopsy.⁵ The tumors that most commonly give metastases to the liver include lung; breast; gastrointestinal tract, such as esophageal, gastric, and colorectal; pancreas; and melanoma. Liver metastases usually appear as multiple solid lesions; however, in some cases, it may present as a solitary lesion, confluent masses, and infiltrative lesions that may mimic cirrhosis.⁶ Various imaging modalities may be used in the assessment of presence of hepatic metastases.

On US, liver metastases can have a variety of different appearances. Generally, the majority of the liver metastases present as multiple, solid, hypoechoic lesions from hypovascular tumors such as breast and lung cancer (Figure 31-1). They may show a peripheral hypoechoic rim known as the halo sign, which has been shown to represent a zone of proliferating tumor, a pseudocapsule, and/or compressed liver parenchyma.⁷ Other liver metastases may appear isoechoic, hyperechoic, and with an anechoic cystic component. Hyperechoic lesions are frequently associated with gastrointestinal primary tumors, renal cell carcinoma, and hepatocellular carcinoma (Figure 31-2). Cystic metastases may demonstrate mural solid nodules or thick septations. Calcified metastases present with posterior acoustic shadowing and are usually seen with mucinous adenocarcinoma of the gastrointestinal and genitourinary tracts.⁸

Figure 31-1 A 69-year-old woman with lung cancer. Gray-scale ultrasound image demonstrates replacement of the hepatic parenchyma by multiple small, round, hypoechoic solid lesions, consistent with metastatic disease.

Figure 31-2 A 65-year-old man with colon cancer. Gray-scale ultrasound image demonstrates several hyperechoic solid lesions (arrowheads) within the liver parenchyma, consistent with metastatic disease.

Although US has been widely used to detect liver metastases, its sensitivity in detecting liver metastases is lower than that of CT and MRI. Wernecke and coworkers ⁹ reported a 53% sensitivity of US in the detection of hepatic masses. The application of new technologies such as microbubble intravenous contrast agents that improve the difference between the metastatic lesions and the background liver parenchyma increases the sensitivity of US in detecting hepatic metastases, even though its use is more common in some centers in Europe.¹⁰ Additional limitations of US include being operator-dependent, nonreproducible, and limited by abdominal gas.

On unenhanced CT, the majority of the liver metastases appear as low-attenuating lesions compared with the surrounding liver parenchyma (Figure 31-3). Calcifications may be seen in the metastatic lesions from a primary mucin-secreting tumor of the gastrointestinal tract or ovary as well as after chemotherapy treatment (Figure 31-4). The use of intravenous contrast medium facilitates the distinction between focal lesions and the underlying liver parenchyma, improving the detection and characterization of hepatic lesions.¹¹

Figure 31-3 A 56-year-old woman with melanoma. Axial unenhanced computed tomography (CT) scan shows multiple solid, low-attenuation lesions (arrows) within the liver parenchyma, consistent with metastatic disease.

Figure 31-4 A 44-year-old woman with moderately differentiated adenocarcinoma of the gastroesophageal junction. Axial unenhanced CT scan demonstrates multiple high-attenuation calcified lesions (arrows) within the liver, consistent with metastatic disease.

On enhanced CT, the imaging features of liver metastases will depend on the primary tumor. The most common liver metastases are hypovascular compared with the adjacent liver and appear as low-attenuation lesions on the portal venous phase of imaging, when the surrounding normal liver is at its peak of enhancement (Figures 31-5 and 31-6). It may also present a hypoattenuating halo and areas of hemorrhage and necrosis when the growth exceeds the tumor neovascularity (Figures 31-7 to 31-9). Hypovascular metastases usually originate from primary tumors from the gastrointestinal tract including colon, rectum, esophagus, and stomach and other sites such as lung, pancreas, and prostate.¹²

Figure 31-5 A 65-year-old man with colon cancer. Axial contrast-enhanced CT scan in the portal venous phase of enhancement shows multiple solid, low-attenuation lesions (arrows) when compared with the surrounding liver parenchyma, consistent with metastatic disease.

Figure 31-6 A 41-year-old woman with breast cancer. Axial contrast-enhanced CT scan in the portal venous phase of enhancement shows multiple solid, low-attenuation lesions (arrows) within the liver, consistent with metastatic disease. Note that some lesions present a more hypodense center, probably representing areas of necrosis.

Figure 31-7 A 53-year-old woman with islet cell pancreatic tumor. Axial contrast-enhanced CT scan in the portal venous phase of enhancement shows two solid lesions that present a thin low-attenuating halo (arrows) surrounding an ovoid center of more intense enhancement, consistent with metastatic disease.

Figure 31-8 A 33-year-old woman with melanoma. Axial contrast-enhanced CT scan in the portal venous phase of enhancement shows innumerous hypodense lesions within the liver, consistent with metastatic disease. Note fluid levels in some of the lesions that may represent hemorrhage (arrows).

Figure 31-9 A 56-year-old woman with ovarian cancer. Axial contrast-enhanced CT scan in the portal venous phase of enhancement shows two large metastatic liver lesions with peripheral enhancement of the solid portions and central hypodensity representing areas of necrosis (arrows).

Alternatively, the hepatic metastases with increased arterial flow relative to normal liver are best seen as hypervascular lesions during the arterial dominant phase of enhancement. Moreover, they may show washout and become hypoattenuating on delayed images (Figure 31-10). Hypervascular metastases usually originate from renal cell carcinomas and neuroendocrine tumors. Other primary tumors that may present with hypervascular liver metastases include medullary thyroid cancer, melanoma, and gastrointestinal stromal tumors.¹³

Figure 31-10 A 54-year-old woman with gastric carcinoid tumor. A, Axial contrast-enhanced CT scan shows few lesions that present intense early enhancement in the arterial phase of enhancement (arrows) compared with the background liver parenchyma, characterizing hypervascular metastases. Axial contrast-enhanced CT scans in the portal venous (B) and delayed (C) phases of enhancement show that the lesions are progressively less conspicuous (arrows) than the background liver parenchyma.

The reported accuracy of CT in detecting hepatic metastases ranges from 75% to 96% based on studies with patients with colorectal cancer.^14,¹⁵ The limitations of CT include radiation exposure and the risk of adverse reaction with the use of iodine intravenous contrast agents.

On MRI, hepatic metastases may have a variable appearance. The majority of liver metastases appear as low signal intensity on unenhanced T1-weighted images. Some tumors that may contain melanin or fat, such as metastases from melanoma and liposarcomas, respectively, can appear hyperintense on T1-weighted images. Hemorrhagic metastases may also appear hyperintense on T1-weighted images. On T2-weighted images, most liver metastases appear with high signal intensity (Figure 31-11). Lesions with central necrosis or cystic metastases can result in even higher signal intensity in T2-weighted images, whereas calcified lesions may be hypointense on T2-weighted images.¹⁶

Figure 31-11 A 62-year-old woman with colon cancer. A, Axial T1-weighted magnetic resonance imaging (MRI) demonstrates two dominant low–signal intensity lesions (arrows) in the liver. B, Axial T2-weighted MRI demonstrates two dominant metastatic foci of high signal intensity (arrows) in the liver. C-E, Axial postcontrast T1-weighted dynamic MRI obtained after the intravenous injection of contrast during the arterial (C), portal venous (D), and delayed (E) phases demonstrate early rim enhancement (arrows in C), hypointense lesions in the portal venous phase of enhancement (arrows in D) compared with the background liver, and subsequent washout of the rim in later images and a progressive accumulation of contrast in the central portion of the lesion (arrows in E).

After intravenous injection of gadolinium, most liver metastases show a peripheral ring of enhancement and are seen in the portal venous phase of imaging as hypointense lesions in comparison with the enhancing surrounding liver parenchyma (see Figure 31-11). Larger lesions may show cauliflower-like enhancement. The hypervascular metastases appear as foci of intense enhancement versus the background liver parenchyma during the arterial phase of enhancement (Figure 31-12). The presence of washout of the contrast from the lesion on delayed images is highly suspicious for malignancy.¹⁷ The reported sensitivity of MRI for the evaluation of suspected hepatic metastases ranges from 80% to 99%.^18,¹⁹ The limitations of MRI include restriction to big centers and contraindication for patients with pacemakers and ferromagnetic implants.